상세 보기
Integrative Molecular Analysis to Predict Clinical Benefit of Everolimus in Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs)
- Han, Miran;
- Lee, Eunbyeol;
- Shin, Ji Eun;
- Kwon, Min Suk;
- Lim, Sung Hee;
- ... Hong, Jung Yong;
- ... Kim, Seung Tae
WEB OF SCIENCE
2SCOPUS
2초록
Introduction Neuroendocrine tumors (NETs) are rare and heterogeneous. Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is widely used in gastrointestinal and pancreatic NETs (GEP-NETs). Owing to the lack of validated biomarkers, exploratory analyses of molecular pathways may help identify subgroups that derive clinical benefit from everolimus. Methods We conducted a retrospective observational cohort study of patients with GEP-NETs who received everolimus and underwent tumor next-generation sequencing (NGS). Genomic alterations were categorized into seven predefined signaling pathways (PI3K/AKT/mTOR, MAPK, DNA damage repair (DDR), developmental, epigenetic regulation, JAK-STAT, and cell-cycle regulation), and patients were classified as mutated (>= 1 alteration) or wild-type. Clinical outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Associations between pathway alterations and outcomes were assessed.Results Twenty-eight patients were included. Median PFS was 26.4 months (95% CI, 17.3-37.1) and median OS was 41.0 months (95% CI, 36.6-not reached [NR]). Alterations in the PI3K/AKT/mTOR pathway were associated with more favorable treatment outcomes, including a higher ORR (47.6% vs. 14.3%; OR, 5.17; 95% CI, 0.49-275.05; p=0.191) and a significantly higher DCR (85.7% vs. 28.6%; OR, 13.0; 95% CI, 1.40-199.5; p=0.009). Survival outcomes also tended to be longer in this group compared with wild-type tumors, with median OS of 59.0 vs. 40.8 months (p=0.321) and median PFS of 26.4 vs. 18.6 months (p=0.858). In contrast, alterations in DDR-related genes were associated with lower ORR and DCR, while alterations in cell-cycle regulation pathways were associated with shorter OS and PFS and numerically lower response rates. No significant differences in survival or response outcomes were observed for MAPK, JAK-STAT, epigenetic, or developmental pathways.Conclusions Pathway-level genomic alterations were associated with differential clinical benefit from everolimus in GEP-NETs, with PI3K/AKT/mTOR alterations suggesting greater benefit, while DDR and cell-cycle alterations indicated reduced benefit. Despite the small cohort, these findings support the potential of pathway-based biomarkers and warrant prospective validation.
키워드
- 제목
- Integrative Molecular Analysis to Predict Clinical Benefit of Everolimus in Patients With Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs)
- 저자
- Han, Miran; Lee, Eunbyeol; Shin, Ji Eun; Kwon, Min Suk; Lim, Sung Hee; Hong, Jung Yong; Kim, Seung Tae
- 발행일
- 2026-03
- 유형
- Article
- 저널명
- Cancer Control
- 권
- 33
- 언어
- ENG
- 출판사
- SAGE PUBLICATIONS INC
- 발행국가
- 미국
- ISSN
- E 1526-2359
P 1073-2748